Federal cannabis legalization might reduce conventional pharmaceutical sales by billions of dollars according to a new study conducted by researchers from California Polytechnic State University and the University of New Mexico.
The study, titled “U.S. Cannabis Laws Projected to Cost Generic and Brand Pharmaceutical Firms Billion,” examined the performance of publicly traded pharmaceutical companies after medical or recreational legalization actions.
